Pocai A

Title : Phase 1 Trials of PNPLA3 siRNA in I148M Homozygous Patients with MAFLD -

Author(s) : Fabbrini E , Rady B , Koshkina A , Jeon JY , Ayyar VS , Gargano C , DiProspero N , Wendel S , Hegge J , Hamilton H , Ding ZM , Afrazi M , Nicholas A , Pei T , Nakano M , Ouchi S , Saito Y , Yamashita A , Tamamura R , Salazar H , Shapiro C , Yoshihara T , Yonemura T , Inoue S , Matsuoka O , Erion M , Pocai A , Makimura H

Ref : N Engl J Med , 391 :475 , 2024

PubMedID: 39083780

Title : A comparative study of the binding properties, dipeptidyl peptidase-4 (DPP-4) inhibitory activity and glucose-lowering efficacy of the DPP-4 inhibitors alogliptin, linagliptin, saxagliptin, sitagliptin and vildagliptin in mice - Berger_2018_Endocrinol.Diabetes.Metab_1_e00002

Author(s) : Berger JP , SinhaRoy R , Pocai A , Kelly TM , Scapin G , Gao YD , Pryor KAD , Wu JK , Eiermann GJ , Xu SS , Zhang X , Tatosian DA , Weber AE , Thornberry NA , Carr RD

Ref : Endocrinol Diabetes Metab , 1 :e00002 , 2018

Abstract :

PubMedSearch : Berger_2018_Endocrinol.Diabetes.Metab_1_e00002

PubMedID: 30815539

Gene_locus related to this paper: human-DPP4

Pocai A

References (2)

1. Phase 1 Trials of PNPLA3 siRNA in I148M Homozygous Patients with MAFLD -

2. A comparative study of the binding properties, dipeptidyl peptidase-4 (DPP-4) inhibitory activity and glucose-lowering efficacy of the DPP-4 inhibitors alogliptin, linagliptin, saxagliptin, sitagliptin and vildagliptin in mice - Berger_2018_Endocrinol.Diabetes.Metab_1_e00002